Sharon Elkobi
Corporate Officer/Principal bij CHEMOMAB THERAPEUTICS LTD.
Profiel
Sharon Elkobi is Vice President-Business Development of Chemomab Therapeutics Ltd.
In the past she occupied the position of Vice President-Business Development at Neurim Pharmaceuticals Ltd.
She received a graduate degree and an MBA from Tel-Aviv University.
Actieve functies van Sharon Elkobi
Bedrijven | Functie | Begin |
---|---|---|
CHEMOMAB THERAPEUTICS LTD. | Corporate Officer/Principal | 01-01-2019 |
Eerdere bekende functies van Sharon Elkobi
Bedrijven | Functie | Einde |
---|---|---|
Neurim Pharmaceuticals Ltd.
Neurim Pharmaceuticals Ltd. BiotechnologyHealth Technology Neurim Pharmaceuticals Ltd. is a neuroscience drug discovery and development company. The company provides Circadin, a prolonged release melatonin for insomnia. Its products include orlogin, for circadian rhythm disorders; Neu-120, which has been developed as adjunct therapy to levodopa in patients with motor fluctuations; Neu-P11, a melatonin agonist binds with high affinity to melatonin receptors; and Neu-105 for the treatment of asthma. The company was founded in 1991 by Nava Zisapel and Yehuda Zisapel and is headquartered in Tel-Aviv, Israel. | Corporate Officer/Principal | - |
Opleiding van Sharon Elkobi
Tel-Aviv University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
CHEMOMAB THERAPEUTICS LTD. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Neurim Pharmaceuticals Ltd.
Neurim Pharmaceuticals Ltd. BiotechnologyHealth Technology Neurim Pharmaceuticals Ltd. is a neuroscience drug discovery and development company. The company provides Circadin, a prolonged release melatonin for insomnia. Its products include orlogin, for circadian rhythm disorders; Neu-120, which has been developed as adjunct therapy to levodopa in patients with motor fluctuations; Neu-P11, a melatonin agonist binds with high affinity to melatonin receptors; and Neu-105 for the treatment of asthma. The company was founded in 1991 by Nava Zisapel and Yehuda Zisapel and is headquartered in Tel-Aviv, Israel. | Health Technology |